EANS-Adhoc: SYGNIS Pharma AG / SYGNIS announces intended changes in the Supervisory Board

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information

06.09.2012

SYGNIS announces intended changes in the Supervisory Board

Heidelberg, 6 September 2012 - SYGNIS Pharma AG (Frankfurt: LIOK;
ISIN DE000A1E9B74; Prime Standard) shall, as already announced on 18
July, 2012, acquire 100% ownership of X-Pol Biotech, S.L., by way of
capital increase against contribution in kind and therefore X-Pol
Biotech, S.L., will become a 100% subsidiary of SYGNIS Pharma AG.
According to the business valuation as of today and subject to a
corresponding resolution of the shareholders of SYGNIS Pharma AG, the
existing shareholders of X-Pol Biotech, S.L., will hold 77.5% of all
shares in SYGNIS Pharma AG after the proposed transaction. By an
approving resolution on the Shareholders' Meeting regarding the
therefore necessary capital increase against contribution in kind the
Shareholders' Meeting will create the fundamental conditions for a
significant change of the shareholder structure of SYGNIS Pharma AG.

In the event the Shareholders' Meeting approves the planned capital
increase of the Company against contribution in kind, the current
Members of the Supervisory Board Prof. Dr. Friedrich von Bohlen und
Halbach, Prof. Dr. Christof Hettich, Prof. Dr. Werner Hacke, Prof.
Dr. Wolfgang Hartwig, Prof. Dr. Andrea Pfeifer and Dr. Wolf-Dieter
Starp have notified the Management Board of SYGNIS Pharma AG
subsequently to their Supervisory Board Meeting of 6 September, 2012,
about their intention to resign from office with effect of the end of
the Shareholders' Meeting approving the capital increase against
contribution in kind. By intending to resign from office the needed
reorientation of SYGNIS Pharma AG shall be supported. Prof. Dr.
Friedrich von Bohlen und Halbach as well as Dr. Wolf-Dieter Starp
intend to seek for re- election into the Supervisory Board.

For further information please contact:

|Peter Willinger |
|Co-CEO/CFO |
|Tel: +49 (0) 6221-454 836 |
|Email: willinger@sygnis.de |

### Disclaimer

This publication is intended for information only and constitutes
neither an offer to sell nor an invitation to buy securities. Some
statements included in this press release, relating neither to
proven financial results nor other historical data, should be
viewed as forward-looking, i.e. not definite. Such statements are
mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees
since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other
factors as a consequence of which the actual results, plans and
goals of SYGNIS Pharma AG may deviate greatly from the
established conclusions or implied predictions contained in
such statements. SYGNIS does not undertake to publicly update
or revise these statements in the light of new information or
future results or for any other reason. ###

Further inquiry note:
Marc Risch
Telefon: +49 (6221) 454 - 737
E-Mail: Marc.Risch@sygnis.de

end of announcement euro adhoc
--------------------------------------------------------------------------------

issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: free trade: Hannover, Berlin, München, Hamburg, Düsseldorf,
Stuttgart, regulated dealing/prime standard: Frankfurt
language: English